Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Francois Guilhot; Francoise Rigal-Huguet; Joelle Guilhot; Agnes-Paule Guerci-Bresler; Frederic Maloisel; Delphine Rea; Valerie Coiteux; Martine Gardembas; Christian Berthou; Anne Vekhoff; Eric Jourdan; Marc Berger; Loic Fouillard; Magda Alexis; Laurence Legros; Philippe Rousselot; Alain Delmer; Pascal Lenain; Martine Escoffre Barbe; Emmanuel Gyan; Claude-Eric Bulabois; Viviane Dubruille; Bertrand Joly; Bertrand Pollet; Pascale Cony-Makhoul; Hyacinthe Johnson-Ansah; Melanie Mercier; Denis Caillot; Aude Charbonnier; Jean-Jacques Kiladjian; Jacques Chapiro; Amelie Penot; Veronique Dorvaux; Iona Vaida; Alberto Santagostino; Lydia Roy; Hacene Zerazhi; Eric Deconinck; Herve Maisonneuve; Isabelle Plantier; Delphine Lebon; Yazid Arkam; Nathalie Cambier; Kamel Ghomari; Jean-Michel Miclea; Sylvie Glaisner; Jean-Michel Cayuela; Jean-Claude Chomel; Marc Muller; Ludovic Lhermitte; Marc Delord; Claude Preudhomme; Gabriel Etienne; Francois-Xavier Mahon; Franck- Emmanuel Nicolini

doi:10.1038/s41375-020-01117-w

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Francois Guilhot, Francoise Rigal-Huguet, Joelle Guilhot, Agnes-Paule Guerci-Bresler, Frederic Maloisel, Delphine Rea, Valerie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff, Eric Jourdan, Marc Berger, Loic Fouillard, Magda Alexis, Laurence Legros, Philippe Rousselot, Alain Delmer, Pascal Lenain, Martine Escoffre Barbe, Emmanuel GyanClaude-Eric Bulabois, Viviane Dubruille, Bertrand Joly, Bertrand Pollet, Pascale Cony-Makhoul, Hyacinthe Johnson-Ansah, Melanie Mercier, Denis Caillot, Aude Charbonnier, Jean-Jacques Kiladjian, Jacques Chapiro, Amelie Penot, Veronique Dorvaux, Iona Vaida, Alberto Santagostino, Lydia Roy, Hacene Zerazhi, Eric Deconinck, Herve Maisonneuve, Isabelle Plantier, Delphine Lebon, Yazid Arkam, Nathalie Cambier, Kamel Ghomari, Jean-Michel Miclea, Sylvie Glaisner, Jean-Michel Cayuela, Jean-Claude Chomel, Marc Muller, Ludovic Lhermitte, Marc Delord, Claude Preudhomme, Gabriel Etienne, Francois-Xavier Mahon, Franck- Emmanuel Nicolini

Population Health Sciences

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Original language	English
Pages (from-to)	2332-2345
Journal	Leukemia
Volume	35
Issue number	8
DOIs	https://doi.org/10.1038/s41375-020-01117-w
Publication status	Published - Aug 2021

Access to Document

10.1038/s41375-020-01117-w

Cite this

Guilhot, F., Rigal-Huguet, F., Guilhot, J., Guerci-Bresler, A.-P., Maloisel, F., Rea, D., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., Jourdan, E., Berger, M., Fouillard, L., Alexis, M., Legros, L., Rousselot, P., Delmer, A., Lenain, P., Escoffre Barbe, M., ... Nicolini, F. E. (2021). Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, 35(8), 2332-2345. https://doi.org/10.1038/s41375-020-01117-w

@article{6b368715cdd64d2d8acaefe966796429,

title = "Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial",

author = "Francois Guilhot and Francoise Rigal-Huguet and Joelle Guilhot and Agnes-Paule Guerci-Bresler and Frederic Maloisel and Delphine Rea and Valerie Coiteux and Martine Gardembas and Christian Berthou and Anne Vekhoff and Eric Jourdan and Marc Berger and Loic Fouillard and Magda Alexis and Laurence Legros and Philippe Rousselot and Alain Delmer and Pascal Lenain and {Escoffre Barbe}, Martine and Emmanuel Gyan and Claude-Eric Bulabois and Viviane Dubruille and Bertrand Joly and Bertrand Pollet and Pascale Cony-Makhoul and Hyacinthe Johnson-Ansah and Melanie Mercier and Denis Caillot and Aude Charbonnier and Jean-Jacques Kiladjian and Jacques Chapiro and Amelie Penot and Veronique Dorvaux and Iona Vaida and Alberto Santagostino and Lydia Roy and Hacene Zerazhi and Eric Deconinck and Herve Maisonneuve and Isabelle Plantier and Delphine Lebon and Yazid Arkam and Nathalie Cambier and Kamel Ghomari and Jean-Michel Miclea and Sylvie Glaisner and Jean-Michel Cayuela and Jean-Claude Chomel and Marc Muller and Ludovic Lhermitte and Marc Delord and Claude Preudhomme and Gabriel Etienne and Francois-Xavier Mahon and Nicolini, {Franck- Emmanuel}",

year = "2021",

month = aug,

doi = "10.1038/s41375-020-01117-w",

language = "English",

volume = "35",

pages = "2332--2345",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature [academic journals on nature.com]",

number = "8",

}

Guilhot, F, Rigal-Huguet, F, Guilhot, J, Guerci-Bresler, A-P, Maloisel, F, Rea, D, Coiteux, V, Gardembas, M, Berthou, C, Vekhoff, A, Jourdan, E, Berger, M, Fouillard, L, Alexis, M, Legros, L, Rousselot, P, Delmer, A, Lenain, P, Escoffre Barbe, M, Gyan, E, Bulabois, C-E, Dubruille, V, Joly, B, Pollet, B, Cony-Makhoul, P, Johnson-Ansah, H, Mercier, M, Caillot, D, Charbonnier, A, Kiladjian, J-J, Chapiro, J, Penot, A, Dorvaux, V, Vaida, I, Santagostino, A, Roy, L, Zerazhi, H, Deconinck, E, Maisonneuve, H, Plantier, I, Lebon, D, Arkam, Y, Cambier, N, Ghomari, K, Miclea, J-M, Glaisner, S, Cayuela, J-M, Chomel, J-C, Muller, M, Lhermitte, L, Delord, M, Preudhomme, C, Etienne, G, Mahon, F-X & Nicolini, FE 2021, 'Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial', Leukemia, vol. 35, no. 8, pp. 2332-2345. https://doi.org/10.1038/s41375-020-01117-w

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. / Guilhot, Francois; Rigal-Huguet, Francoise; Guilhot, Joelle et al.
In: Leukemia, Vol. 35, No. 8, 08.2021, p. 2332-2345.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

AU - Guilhot, Francois

AU - Rigal-Huguet, Francoise

AU - Guilhot, Joelle

AU - Guerci-Bresler, Agnes-Paule

AU - Maloisel, Frederic

AU - Rea, Delphine

AU - Coiteux, Valerie

AU - Gardembas, Martine

AU - Berthou, Christian

AU - Vekhoff, Anne

AU - Jourdan, Eric

AU - Berger, Marc

AU - Fouillard, Loic

AU - Alexis, Magda

AU - Legros, Laurence

AU - Rousselot, Philippe

AU - Delmer, Alain

AU - Lenain, Pascal

AU - Escoffre Barbe, Martine

AU - Gyan, Emmanuel

AU - Bulabois, Claude-Eric

AU - Dubruille, Viviane

AU - Joly, Bertrand

AU - Pollet, Bertrand

AU - Cony-Makhoul, Pascale

AU - Johnson-Ansah, Hyacinthe

AU - Mercier, Melanie

AU - Caillot, Denis

AU - Charbonnier, Aude

AU - Kiladjian, Jean-Jacques

AU - Chapiro, Jacques

AU - Penot, Amelie

AU - Dorvaux, Veronique

AU - Vaida, Iona

AU - Santagostino, Alberto

AU - Roy, Lydia

AU - Zerazhi, Hacene

AU - Deconinck, Eric

AU - Maisonneuve, Herve

AU - Plantier, Isabelle

AU - Lebon, Delphine

AU - Arkam, Yazid

AU - Cambier, Nathalie

AU - Ghomari, Kamel

AU - Miclea, Jean-Michel

AU - Glaisner, Sylvie

AU - Cayuela, Jean-Michel

AU - Chomel, Jean-Claude

AU - Muller, Marc

AU - Lhermitte, Ludovic

AU - Delord, Marc

AU - Preudhomme, Claude

AU - Etienne, Gabriel

AU - Mahon, Francois-Xavier

AU - Nicolini, Franck- Emmanuel

PY - 2021/8

Y1 - 2021/8

U2 - 10.1038/s41375-020-01117-w

DO - 10.1038/s41375-020-01117-w

M3 - Article

SN - 0887-6924

VL - 35

SP - 2332

EP - 2345

JO - Leukemia

JF - Leukemia

IS - 8

ER -

Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D et al. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w